Media Articles Related to Bystolic (Nebivolol)
ESH/ESC Publish Hypertension Guidelines
Source: Medscape Medical News Headlines [2013.06.15]
The new guidelines make <140 mm Hg the treatment target for all individuals, with a few minor exceptions, and say that all the drug classes have a role in reducing blood pressure. In addition, the ESH/ESC guidelines emphasize a role for ABPM and reiterate their emphasis on combination therapy.
Vitamin D Can Help Prevent Hypertension
Source: Health News from Medical News Today [2013.06.15]
The world's largest study to examine the link between vitamin D levels and hypertension has found that low levels of Vitamin D can be a major cause of hypertension. Researchers presented their findings at the annual conference of the European Society of Human Genetics (ESHG). Data were gathered from 35 studies, which included more than 155,000 participants from different parts of Europe and North America. Dr. Vimal Karani S, from the Institute of Child Health, University College London, London, UK, led the study...
Hypertension Risk Drops with Volunteer Work (CME/CE)
Source: MedPageToday.com - medical news plus CME for physicians [2013.06.14]
(MedPage Today) -- Older adults had a significantly lower risk of developing hypertension if they performed at least 200 hours of volunteer service in the previous year, a longitudinal survey showed.
Link Clarified Between Hypertension And Vitamin D Deficiency
Source: Hypertension News From Medical News Today [2013.06.12]
Low levels of vitamin D can trigger hypertension, according to the world's largest study to examine the causal association between the two. Although observational studies have already shown this link, a large-scale genetic study was necessary before the cause and effect could be proven, the annual conference of the European Society of Human Genetics (ESHG) heard. Dr...
Source: MedicineNet Cirrhosis Specialty [2013.06.10]
Title: Portal Hypertension
Category: Diseases and Conditions
Created: 1/31/2005 8:20:00 AM
Last Editorial Review: 6/10/2013 12:00:00 AM
Published Studies Related to Bystolic (Nebivolol)
beta-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. [2011.08]
The use of beta-receptor blockers in peripheral arterial disease is controversial for their impact on vasomotor tone... In the direct comparison, there was no significant difference between nebivolol and metoprolol.
Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. [2011.07]
CONCLUSION: The increases in ICD, ACD and ABI with nebivolol suggest that this medication does not have negative effects on hypertensive patients with symptomatic PAD, and can be used for treatment of hypertension in these patients at high cardiovascular risk without reducing the walking ability.
Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial. [2011.06]
OBJECTIVE: The aim of the present study is to compare the antihypertensive effects of carvedilol and nebivolol in mild-to-moderate hypertensive patients... CONCLUSION: Although both carvedilol and nebivolol effectively decreased blood pressure compared to placebo, they showed similar efficacy for lowering blood pressure.
Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. [2011.06]
The aim of this study was to investigate the effects of the vasodilating beta-blocker nebivolol and the cardioselective beta-blocker metoprolol succinate on aortic blood pressure and left ventricular wall thickness... This proof-of-principle study provides evidence to suggest that beta-blockers with vasodilating properties may offer advantages over conventional beta-blockers in antihypertensive therapy; however, this remains to be tested in a larger trial.
The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension. [2011.05]
This study sought to determine if metoprolol succinate ER (MET), and nebivolol (NEB), a beta1-AR with increased bioavailability of nitric oxide (NO), would have differing effects on plasma asymmetric dimethylarginine concentration in hypertensives. It was hypothesized that NEB, a beta1-AR antagonist and beta3-AR agonist with NO-releasing properties, and MET, only a beta1-AR antagonist, would have different effects on plasma asymmetric dimethylarginine (ADMA) concentration...
Clinical Trials Related to Bystolic (Nebivolol)
The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension [Recruiting]
High blood pressure (hypertension) is called the "silent killer" because many people do not
know they have it, and do not know when it is well controlled. Unfortunately, over time
uncontrolled hypertension can cause irreversible organ damage that can lead to heart attack,
stroke, heart failure, and kidney failure. If a person cannot control their blood pressure
with diet and exercise, doctors often prescribe medications to help control the blood
pressure. Nebivolol is a medication that has been recently approved by the FDA for the
treatment of hypertension. Our study will investigate whether treatment with nebivolol, as
compared to another medication called metoprolol, in African Americans with hypertension
will be more effective in protecting blood vessels against the harmful effects of high blood
Over time high blood pressure causes hardening of the arteries (atherosclerosis) which leads
to narrowing of the blood vessels and reduces blood flow to our organs. Arteries also relax
and contract naturally, which further changes the blood supply. When arteries are narrowed,
exercise can bring on a condition in which the blood supply is inadequate, and this might
result in the sensation of pain.
Cells lining our blood vessels produce a variety of substances that normally cause arteries
to relax. Two of these substances are called nitric oxide (NO) and endothelium-derived
hyperpolarizing factor (EDHF). We are trying to determine the nature of these substances in
African Americans with high blood pressure and how it is affected by nebivolol and
metoprolol. One way to determine this is to inject drugs such as L-NMMA
(N(G)-monomethyl-L-arginine) or TEA (tetraethylammonium chloride), which block the
production of NO and EDHF respectively, and then study what happens to the blood flow at
rest and during exercise. It is our thought that nebivolol, in comparison to metoprolol,
will increase the substances that naturally cause arteries to relax and improve blood
Comparative Effects of Nebivolol and Metoprolol on Femal Sexual Function [Recruiting]
Beta-blockers (BB) are an important treatment for high blood pressure and heart disease.
However beta-blockers can cause sexual dysfunction (SD) and this common side effect limits
successful use of this class of medications. Sexual side effects often result in drug
discontinuation, compromising therapy goals. The investigators are conducting the study to
determine if nebivolol, a newer beta blocker that is selective for receptors in the heart
and causes vasodilation in the body causes fewer sexual side effects, or even improves
sexual function, compared with metoprolol succinate.
Comparative Effects of Nebivolol Versus Placebo on Sodium Sensitivity of Blood Pressure in Hispanic Postmenopausal Women With Hypertension [Not yet recruiting]
2. 1 Research objectives:
The objective of this randomized, placebo-controlled, 2 period crossover clinical trial is
to determine the effects of nebivolol versus placebo on ambulatory blood pressure, the blood
pressure response to dietary sodium loading, and renal handling of an acute sodium load in
postmenopausal women with hypertension.
2. 1.1 Hypothesis:
Nebivolol will result in a blunted response of blood pressure to oral sodium administration
and improved handling of an intravenous sodium load in comparison with placebo in
hypertensive postmenopausal women.
2. 2 Research plan:
2. 2.1 Study design
The study will consist of a randomized crossover trial of the effects on salt sensitivity of
nebivolol. All study procedures will be carried out under the direct supervision of the
Principal Investigator in the outpatient and inpatient research unit of the University of
Miami Division of Clinical Pharmacology.
2. 2.2 Primary endpoints:
1. Change and percentage change in systolic, diastolic and mean blood pressure by ABPM
from final day of low sodium to the final day of high sodium in nebivolol versus
2. Differences in renal sodium excretion in response to an acute sodium load during
treatment with either nebivolol or placebo.
2. 2.3 Secondary endpoints
1. Change in clinic blood pressure following 4 weeks of outpatient nebivolol versus
2. Change in weight from final day of low sodium to the final day of high sodium in
nebivolol versus placebo
3. Change in 24-hour sodium and potassium excretion from last day of low sodium to last
day of high sodium
4. Asymmetrical dimethylarginine (ADMA)
Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients [Recruiting]
The purpose of this study is to determine if Nebivolol improves microvascular perfusion in
skeletal muscle during exercise in hypertensive patients and whether this improvement is
accompanied by reduction in vascular oxidative stress or increased endothelial nitric oxide
synthase (eNOS) expression in humans.
Nebivolol in the Supine Hypertension of Autonomic Failure [Recruiting]
The purpose of this study is to evaluate the effect of the antihypertensive drug, nebivolol
(Bystolic), compared to metoprolol (Lopressor) and sildenafil (Viagra) on blood pressure in
patients with autonomic failure and supine hypertension.
Reports of Suspected Bystolic (Nebivolol) Side Effects
Blood Pressure Increased (17),
Loss of Consciousness (15),
Heart Rate Decreased (13),
Abdominal Distension (10), more >>